IP Library › Granted Patent US 12,310,933
Granted Patent B2
US 12,310,933 · App. 17/248,432 · Granted May 27, 2025

Treatment of demyelinating disorders

Inventors: Sharon Way (Chicago, IL); Benjamin Clayton (Chicago, IL); Brian Popko (Chicago, IL)
Assignee: The University of Chicago
A61K31/155A61K9/0019A61K31/136A61K31/137A61K31/225A61K31/277A61K31/4409A61K38/03A61K38/215A61K39/3955A61K45/06A61K2039/505
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,310,933
App. No.
17/248,432
Granted
May 27, 2025
Kind
B2
Abstract

This invention discloses methods and compositions for the treatment of demyelinating disorders. Specifically, the invention relates to the use guanabenz or guanabenz derivative for treating demyelinating disorders.

Claims (3)

1. A method of treating Multiple Sclerosis, acute disseminated encephalomyelitis, periventricular leukomalacia, periventricular white matter injury, Tabes Dorsalis, Devic's disease, optic neuritis, progressive multifocal leukoencephalopathy, transverse myelitis, chronic inflammatory demyelinating polyneuropathy, anti-MAG peripheral neuropathy, adrenoleukodystrophy, adrenomyeloneuropathy, Guillain-Barré Syndrome, central pontine myelinolysis, and/or diffuse white matter injury, the method comprising administering to a subject in need thereof an effective amount of a compound of the Formula:

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the demyelinating disorder is multiple sclerosis.

Assignments (2)
CONFIRMATORY LICENSE Recorded Nov 14, 2023
From: UNIVERSITY OF CHICAGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065566/0077 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2021
From: WAY, SHARON; CLAYTON, BENJAMIN; POPKO, BRIAN
To: THE UNIVERSITY OF CHICAGO
Reel/Frame 055019/0940 →
Continuity (3)
Continuation 14773088
Provisional Application 61772875 · Mar 5, 2013
Related Publication 20210161836A1 · Jun 3, 2021
References Cited (26)
US 7932422B2 · Bertolotti et al. · 2011 [cited by applicant]
US 9682943B2 · Guedat et al. · 2017 [cited by applicant]
US 20080089861A1 · Went · 2008 [cited by examiner]
US 20080131483A1 · Abdulrazik · 2008 [cited by applicant]
US 20090227646A1 · Davis et al. · 2009 [cited by applicant]
US 20100172869A1 · Masuoka · 2010 [cited by applicant]
US 20120196931A1 · Lukashev et al. · 2012 [cited by applicant]
US 20120225070A1 · Smith et al. · 2012 [cited by applicant]
WO WO1995001096 · 1995 [cited by applicant]
WO WO2001025192A1 · 2001 [cited by examiner]
WO WO2011019845 · 2011 [cited by applicant]
WO WO2012112933 · 2012 [cited by applicant]
WO WO2012112933A1 · 2012 [cited by examiner]
WO WO2014108520 · 2014 [cited by applicant]
Tribouillard-Tanvier D, Béringue V, Desban N, Gug F, Bach S, Voisset C, Galons H, Laude H, Vilette D, Blondel M. Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions. PLoS One. Apr. … [cited by examiner]
Taconic Biosciences Inc. “Sprague Dawely” Apr. 15, 2004. https://www.taconic.com/rat-model/sprague-dawley (Year: 2004). [cited by examiner]
Behan et al., “The sad plight of multiple sclerosis research (low on fact, high on fiction): critical data to support it being a neurocristopathy” [cited by applicant]
Constantinescu et al., [cited by applicant]
Constantinescu et al., [cited by applicant]
International Search Report and Written Opinion issued in PCT/US14/20896, mailed on Jun. 10, 2014. [cited by applicant]
Maier et al., [cited by applicant]
Ransohoff, R. M., “Animal models of multiple sclerosis: the good, the bad and the bottom line” [cited by applicant]
Robinson et al., [cited by applicant]
Steinman et al., [cited by applicant]
'T Hart et al., “Modelling of multiple sclerosis: lessons learned in a non-human primate” [cited by applicant]
Wekerle et al., “Animal models of multiple sclerosis” [cited by applicant]